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ERLUX assay 
T47D-Kbluc cells were routinely grown in growth media (GM) consisting of RPMI (L-glutamine 
free), which contained glucose (2.5 g/L; Sigma Aldrich), HEPES (10 mM), sodium pyruvate (1 
mM; Sigma Aldrich), insulin (0.2 U/mL), 10% foetal bovine serum (FBS), penicillin (100 U/mL), 
streptomycin (100 μg/mL), and L-glutamine (2 mM). Briefly, T47D-KBluc cells were transferred 
into a low-estrogen condition by using pre-assay media (PAM; identical to GM, but 10% carcol-
dextran stripped FBS, no antibiotics) one week prior to testing. 10 000 cells/well in PAM were 
seeded into white, sterile, 96-well plates with lids (Greiner BIO-ONE Ltd.). Over the next 24 h 
the cells were allowed to attach. PAM was then removed from the plate and the samples, positive 
controls (E2, genistein), and solvent control (0.5% DMSO) were applied in dosing media (DM; 
phenol-red free RPMI, 5% carcol-dextran stripped FBS, no antibiotics). Eight replicates of 
solvent controls plus an antiestrogen, fulvestrant (1 μM), and eight replicates of the positive 
control plus fulvestrant (1 μM), were used to monitor the background estrogenicity in each assay. 
The performance of the assay was considered to be satisfactory when the antiestrogen sufficiently 
blocked the estrogenic effect of the positive control. 
 
Cytotoxicity assessment in the ERLUX assay 
40 000 cells/well were seeded and incubated as described for the ERLUX assay and 24 h after the 
application of the treatment, the DM was gently removed and replaced by 100 L DM and an 
additional 20 L of MTT solution (5 mg/mL in HBSS) per well. Cells were incubated for 4 h and 
lysed afterwards with 150 L of a mixture consisting of 250 mL dimethylformamide, 250 mL 
deionised H2O, 100 g sodium dodecyl sulphate, 10 mL glacial acetic acid, and 5 mL hydrochloric 
acid (2 M). The solubilisation solution was adjusted to pH 4.7 [1]. The optical density of the 
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formazan was quantified at 570 nm (Labsystem Multiscan). 40 000 cells/well was chosen for the 
cytotoxicity testing, as the original number of 10 000 cells/well was too low to observe 
mitochondrial activity by the formation of purple coloured formazan. The results of the 
cytotoxicity assay were normalised by subtraction of the background absorbance of the DM (100 
L), the MTT solution (20 L), and 40 000 cells (blank wells). The normalised raw data were 
then divided by the average of on-plate solvent controls (n = 8) and multiplied by 100, to express 
the results as % of viable cells compared to solvent controls.  
 
Modification of the SSRI assay 
The cells (100 000 cells/well) were seeded into poly-D-lysine (50 mg/mL) coated 24-well plates 
(Nunc, Thermo Scientific) and allowed to attach for 48 h at 37 C (5% CO2, humidified 
incubator). The medium was removed and wells were washed with 200 L wash-Krebs-Ringer-
Hepes-buffer [wash-KRH, 120 mM NaCl, 4.7 mM KCl, 2.2 mM Ca2Cl, 10 mM Hepes, 1.2 mM 
KH2PO4, 1.2 mM MgSO4, endotoxin-free water (cell culture grade)]. Test samples were diluted 
with assay KRH identical to wash-KRH except for the addition of D-glucose (10 mM), ascorbic 
acid (100 M), and paragyline (100 M). The highest DMSO concentration in the wells was 1%. 
The test sample in the assay-KRH solution was applied (500 L/well) and cells were incubated 
for 10 min at 37 C, before 5-HT solution (20.5 pmoles 5-HT and 0.1 pmoles [3H]-5-HT) was 
added to each well. Plates were incubated for a further 10 min and washed with ice-cold wash-
KRH (3) before the cells were solubilised in 0.1% NaOH. 
 
Modification of the AChEI assay  
Briefly, 25 L Tris buffer (50 mM, pH 8) was added to all test wells (duplicate columns of 6 
wells/sample). 25 L of test solution were added to the first wells of the columns and by 
removing 25 L from those wells and adding them to the next column; a 1:2 serial dilution was 
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performed. Subsequently, 50 L of Tris buffer, 25 L acetylthiocholiniodide solution (15 mM in 
Millipore water), and 125 L Ellman’s reagent (3 mM in 50 mM Tris–HCl, pH 8, containing 0.1 
M NaCl and 0.02 M MgCl2  6H2O) were added to each well. The plates were mixed on the plate 
shaker for 2 min in the dark, before the absorbance (background reading, spontaneous hydrolysis 
of substrate) was read at 405 nm on a plate reader (Labsystem Multiskan Multisoft). 
Subsequently, 25 L of AChE solution (0.22 U/mL in 50 mM Tris–HCl, pH8, containing 0.1% 
bovine serum albumin) was added to each well. Plates were again mixed in the dark for 2 min on 
the plate shaker and read at 405 nm to determine the development of the resulting, yellow anion 
5,5-thio-2-nitro-benzoic acid. Solutions of acetylthiocholiniodide, DTNB and AChE were freshly 
prepared. 
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Fig. 1S Estrogenicity-guided isolation scheme of the aq. EtOH SE. Chromatographic methods are 
indicated on the left of each fractionation step. Underlined fractions were chosen for further 
fractionation based on estrogenic potential (EC50 values).  
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Fig. 2S AChE inhibition by the crude S. officinalis tincture, the n-hexane, the CHCl3 and the aq-
EtOH SEs and the positive control galanthamine (triangle). Data are from at least three 
independent experiments, tested in duplicate. Error bars represent 95% confidence intervals. *P < 
0.05, significant inhibition (> 0). 
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Fig. 3S ERLUX experiments in the presence of an ER-antagonist fulvestrant. A shows data from 
experiments with crude Salvia officinalis extract (circles) and aq-EtOH SE (triangles) and B 
shows CHCl3 SE (triangle) and n- hexane SE (circles) in combination with fulvestrant (1.0 M, 
antiestrogen), each experiment was done in triplicate. Filled circles represent individual data 
points. Data were fitted using a linear regression model. On-plate controls, positive controls (1.0 
nM estradiol, triangle, n = 8), and E2 in combination with fulvestrant (in 1.0 nM/1.0 M, circles, 
n = 8) are shown next to the y-axis (mean  95% CI).  
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Luteolin-7-O-glucoside 
 
 
 
 
 
Luteolin-7-O-glucuronide 
 
Fig. 4S Chemical structures of luteolin-7-O-glucoside and luteolin-7-O-glucuronide. 
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- 
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3.13-3.37 (m) 
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- 
 
Fig. 5S 1H- and 13C-NMR data for luteolin-7-O-glucuronide (DMSO-d6, 500 MHz/125 MHz). 
Chemical shifts are reported in ppm, J values in Hz.  
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Fig. 6S 1H-NMR spectrum of luteolin-7-O-glucuronide (DMSO-d6, 500 MHz). 
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Fig. 7S 13C-NMR (A) and DEPT-135 (B) spectra of luteolin-7-O-glucuronide (DMSO-d6, 125 
MHz). 
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Fig. 8S The HMQC spectrum of luteolin-7-O-glucuronide (DMSO-d6, 500 MHz). 
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Fig. 9S The COSY spectrum of luteolin-7-O-glucuronide (DMSO-d6, 500 MHz). 
© Georg Thieme Verlag KG · DOI 10.1055/s-0032-1328552 · Planta Med · Rahte S et al. 
 14
 
Fig. 10S The HMBC spectrum of luteolin-7-O-glucuronide (DMSO-d6, 500 MHz). 
 
 
Fig. 11S The (+)-HR-ESI-MS spectrum of luteolin-7-O-glucuronide.  
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Fig. 12S 1H-NMR spectrum of fraction 7.6.7.6 (bottom) and luteolin-7-O-glucoside (DMSO-d6, 
500 MHz). 
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